<DOC>
	<DOCNO>NCT02638259</DOCNO>
	<brief_summary>Demonstrate equivalent efficacy GP2015 EU-authorized Enbrel patient moderate severe , active ( RA ) inadequate response disease modify anti-rheumatic drug ( DMARD ) include methotrexate ( MTX ) .</brief_summary>
	<brief_title>Comparative Efficacy Safety Study GP2015 EnbrelÂ® Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description>Demonstrate equivalent efficacy GP2015 EU-authorized Enbrel patient moderate severe , active ( RA ) inadequate response disease modify anti-rheumatic drug ( DMARD ) include methotrexate ( MTX ) . In addition , data safety profile product , include immunogenicity local tolerability injection site , collect compare . An additional study objective identify potential risk transition Enbrel GP2015 term general safety immunogenicity RA patient</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Patients least 18 year age RA diagnosis accord ACR 1987 ACR/EULAR 20110 criterion &gt; /= 6 month time baseline visit Patient must active disease define DAS28CRP &gt; /=3.2 Patients must CRP level ULN &gt; 5mg/l ) erythrocyte sedimentation rate ( ESR ) &gt; /=28mm/h Patients must inadequate clinical response MTX dose 1025 mg/wk proper dose escalation accord local standard Previous exposure etanercept past Patients functional status class IV accord ACR 1991 revise criterion History active tuberculosis ( TB ) Presence latent ( inactive ) TB detect image and/or QuantiFERONTB Gold test screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Biosimilars</keyword>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>Etanercept</keyword>
</DOC>